Azf's fixed table is approved to increase the treatment of new coronary pneumonia

Our newspaper, Beijing, July 25 (Reporter Chen Haibo) The State Drug Administration issued news on the 25th that according to the relevant provisions of the Drug Management Law, in accordance with the special approval procedures for the drug, the emergency review and approval were conducted. Azf fixed tablets in the Co., Ltd. increase the application for registration of new coronary virus pneumonia.

According to the State Drug Administration, Azf's fixed film is the treatment of oral small molecular virus pneumonia for oral small molecular virus pneumonia. On July 20, 2021, the State Drug Administration has attached conditions to approve adult HIV-1 infection patients with high virus loads with other reverse transliterase inhibitors. This is an attachment to approve new indications for the treatment of adult patients in ordinary new coronary virus pneumonia. Patients should be used strictly under the guidance of the doctor.

It is understood that the attached conditions are approved for listing refers to a disease that is used to be seriously life -threatening and has no effective treatment methods and urgently needed drugs in public health. The data shows the efficacy and can predict its clinical value. It is approved to be listed based on a replacement end, intermediate clinical end point or early clinical trial data when specified that the applicant must fulfill specific conditions.

The State Drug Administration requested that the listing license holders of Azf's settlement to continue to carry out relevant research work, complete the requirements for the qualified conditions within a time limit, and submit subsequent research results in a timely manner.

- END -